Feb 9 (Reuters) – Shield Therapeutics PLC: * SHIELD THERAPEUTICS – FDA GRANTS ADDITIONAL EXCLUSIVITY FOR ACCRUFER * SHIELD THERAPEUTICS : EXCLUSIVITY REMAINS IN PLACE UNTIL 19 DEC 2028 IN ADDITION TO ACCRUFER/FERACCRU PATENT COVERAGE VALID UNTIL MID-2030S Source text: Further company coverage: ;))
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
COPENHAGEN, Feb 9 (Reuters) - Novo Nordisk's shares jumped more than 8% on Monday after telehealth…
SINGAPORE, Feb 9 (Reuters) - Oil prices fell more than 1% on Monday as fears…
Mumbai (Maharashtra) [India], February 09: Agilus Diwine Diagnostics, in association with Agilus (Dr. Phadke Labs,…
By Alessandro Parodi Feb 9 (Reuters) - A consortium led by holding firm Advent and…
Feb 9 (Reuters) - Elon Musk said on Sunday that SpaceX has shifted its focus…
Ludhiana (Punjab) [India], February 09: The Punjab NGO Expo 2026, organised by CityNeeds with the…